LC
JANX icon

Lindbrook Capital’s Janux Therapeutics JANX Stock Holding History

Lindbrook Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$378 Buy
14
+2
+17% +$75 ﹤0.01% 2664
2024
Q4 		$642 Hold
12
– – ﹤0.01% 2565
2024
Q3 		$545 Buy
12
+2
+20% +$87 ﹤0.01% 2645
2024
Q2 		$419 Buy
+10
New +$470 ﹤0.01% 2662
2023
Q3 		– Sell
-125
Closed -$1.48K – 2755
2023
Q2 		$1.48K Buy
+125
New +$1.67K ﹤0.01% 2265

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Lindbrook Capital's JANX Position: Q1 2025 in Review

Lindbrook Capital increased its Janux Therapeutics (JANX) stake by 17% in Q1 2025, buying an estimated $75 and bringing the position to 14 shares worth $378. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Lindbrook Capital first reported a position in JANX in Q2 2023 and has held it in 5 quarters since. The position peaked at $1.48K in Q2 2023. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Lindbrook Capital held 14 shares of Janux Therapeutics worth $378 as of Q1 2025.
  • Lindbrook Capital bought 2 Janux Therapeutics shares in Q1 2025, an estimated $75.
  • Janux Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2664 holding.
  • Lindbrook Capital first reported a position in Janux Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • Lindbrook Capital's Janux Therapeutics position peaked at $1.48K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.